Revati Varma, Jeffrey P. Staab, Eric T. Matey, Jessica A. Wright, Brototo Deb, Konstantinos N. Lazaridis, Lawrence A. Szarka, Kent R. Bailey, Adil E. Bharucha
{"title":"大多数患有肠脑相互作用疾病的患者接受药物治疗时，都会发生严重或中度的药物基因相互作用","authors":"Revati Varma, Jeffrey P. Staab, Eric T. Matey, Jessica A. Wright, Brototo Deb, Konstantinos N. Lazaridis, Lawrence A. Szarka, Kent R. Bailey, Adil E. Bharucha","doi":"10.1111/nmo.14722","DOIUrl":null,"url":null,"abstract":"How variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut- brain interaction is unclear.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"173 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions\",\"authors\":\"Revati Varma, Jeffrey P. Staab, Eric T. Matey, Jessica A. Wright, Brototo Deb, Konstantinos N. Lazaridis, Lawrence A. Szarka, Kent R. Bailey, Adil E. Bharucha\",\"doi\":\"10.1111/nmo.14722\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"How variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut- brain interaction is unclear.\",\"PeriodicalId\":19104,\"journal\":{\"name\":\"Neurogastroenterology & Motility\",\"volume\":\"173 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurogastroenterology & Motility\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/nmo.14722\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurogastroenterology & Motility","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/nmo.14722","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions
How variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut- brain interaction is unclear.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
